5-溴-3-甲基-1,2-苯异噁唑 | 66033-76-9

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并异恶唑
• 中文名称: 5-溴-3-甲基-1,2-苯异噁唑
• 中文别名: 5-溴-3-甲基苯并[D]异恶唑
• 英文名称: 5-bromo-3-methylbenzo[d]isoxazole
• 英文别名: 5-bromo-3-methylbenzisoxazole；5-bromo-3-methyl-1,2-benzoxazole
• CAS: 66033-76-9
• 化学式: C₈H₆BrNO
• 分子量: 212.046
• InChiKey: ITZVIXFFWVROPH-UHFFFAOYSA-N

物化性质

• 熔点：
  43 °C(Solv: ethanol (64-17-5))
• 沸点：
  292.5±20.0 °C(Predicted)
• 密度：
  1.606±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338,P304+P340
• 危险性描述：
  H302

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromo-3-methyl-1,2-benzoxazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-3-methyl-1,2-benzoxazole
CAS number: 66033-76-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H6BrNO
Molecular weight: 212.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-3-甲基-1,2-苯异噁唑 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 四氯化碳 为溶剂， 反应 24.0h， 以63%的产率得到5-bromo-3-(bromomethyl)benzo[d]isoxazole
  参考文献：
  名称：

  [EN] ISOXAZOLINE DERIVATIVES AND THEIR USES IN AGRICULTURE RELATED APPLICATION
  [FR] DÉRIVÉS D'ISOXAZOLINE ET LEURS UTILISATIONS DANS UNE APPLICATION LIÉE À L'AGRICULTURE

  摘要：

  本发明提供了异噁唑啉衍生物及其在农业中的用途；具体而言，本发明提供了具有化学式（I）的化合物，或其立体异构体、N-氧化物或盐，其制备方法，以及含有这些化合物的组合物及其在农业中的用途，特别是作为除草剂活性成分用于控制不受欢迎的植物；其中R1、R2、R3、R4、n、R5、R6和Hy如本发明所述。

  公开号：

  WO2019062802A1
• 作为产物：
  描述：

  2-羟基-5-甲基苯乙酮 在 N-氯代丁二酰亚胺 、 氨 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 24.0h， 生成 5-溴-3-甲基-1,2-苯异噁唑
  参考文献：
  名称：

  [EN] BENZOISOXAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION
  [FR] COMPOSÉS À SUBSTITUANTS BENZISOXAZOLE EN TANT QUE POTENTIALISATEURS ALLOSTÉRIQUES DE MGLUR4, COMPOSITIONS, ET MÉTHODES DE TRAITEMENT DE DYSFONCTIONNEMENTS NEUROLOGIQUES

  摘要：

  作为代谢型谷氨酸受体亚型4（mGluR4）的辅助激活剂/正向变构调节剂有用的化合物；制备这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物的方法，例如，在治疗与谷氨酸功能障碍相关的神经和精神障碍或其他疾病状态中。

  公开号：

  WO2016115282A1

文献信息

• [EN] METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION<br/>[FR] MÉTHODES ET COMPOSÉS DESTINÉS À LA RESTAURATION D'UNE FONCTION DE MUTANTS DE P53
  申请人：PMV PHARMACEUTICALS INC

  公开号：WO2021262684A1

  公开（公告）日：2021-12-30

  Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

  癌基因和肿瘤抑制基因的突变促成了癌症的发展和进展。本公开披露描述了一种恢复p53突变体DNA结合亲和力的化合物和方法。本公开披露的化合物可以结合突变型p53，并恢复p53突变体结合DNA并激活参与肿瘤抑制的下游效应子的能力。披露的化合物可用于减少含有p53突变的癌症的进展。
• Derisking the Cu-Mediated ¹⁸F-Fluorination of Heterocyclic Positron Emission Tomography Radioligands
  作者：Nicholas J. Taylor、Enrico Emer、Sean Preshlock、Michael Schedler、Matthew Tredwell、Stefan Verhoog、Joel Mercier、Christophe Genicot、Véronique Gouverneur

  DOI：10.1021/jacs.7b03131

  日期：2017.6.21

  Molecules labeled with fluorine-18 (18F) are used in positron emission tomography to visualize, characterize and measure biological processes in the body. Despite recent advances in the incorporation of 18F onto arenes, the development of general and efficient approaches to label radioligands necessary for drug discovery programs remains a significant task. This full account describes a derisking approach

  用氟 18 (18F) 标记的分子用于正电子发射断层扫描，以可视化、表征和测量体内的生物过程。尽管最近在将 18F 掺入芳烃方面取得了进展，但开发通用且有效的方法来标记药物发现计划所需的放射性配体仍然是一项重大任务。这个完整的描述描述了杂环正电子发射断层扫描 (PET) 放射性配体的放射合成方法，使用铜介导的 18F 氟化芳基硼试剂与 18F 氟化物作为模型反应。该方法基于一项研究，该研究检查了药物开发中常用的杂环的存在如何影响代表性芳基硼试剂的 18F-氟化效率，以及超过 50 种（杂）芳基硼酸酯的标记。这组数据允许将这种去风险策略应用于七种结构复杂的药物相关含杂环分子的成功放射合成。
• [EN] ORAL COMPLEMENT FACTOR D INHIBITORS<br/>[FR] INHIBITEURS ORAUX DU FACTEUR D DU COMPLÉMENT
  申请人：BIOCRYST PHARM INC

  公开号：WO2021072198A1

  公开（公告）日：2021-04-15

  Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

  揭示了式(I)的化合物及其药学上可接受的盐，这些化合物是裂解系统的抑制剂。还提供了包含这种化合物的药物组合物，以及使用这些化合物和组合物治疗或预防由异常裂解系统活性特征的疾病或状况的方法。
• 一类苯并[d]异恶唑类化合物及其应用
  申请人：中国科学院广州生物医药与健康研究院

  公开号：CN105085427B

  公开（公告）日：2018-06-05

  本发明涉及化学医药技术领域，具体公开了通式(A)所示的一类苯并[d]异恶唑类化合物及其应用。该类化合物可有效抑制BET家族蛋白的溴结构域(bromodomain)，从而阻断BET家族蛋白与染色质组蛋白之间的相互作用，进而调节基因转录，引起下游信号通路的变化，并对多种疾病产生重要影响。因此本发明提供的化合物及组合物可用于制备治疗或预防肿瘤形成、炎症、病毒感染、细胞增值性紊乱、自身免疫性疾病、败血症等疾病的药物。(A)。
• [EN] FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRISTIS<br/>[FR] DERIVES HETEROARYLE CONDENSES UTILISABLES COMME INHIBITEURS DE KINASE P38, NOTAMMENT DANS LE TRAITEMENT DE POLYARTHRITE RHUMATOIDE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2004010995A1

  公开（公告）日：2004-02-05

  Compounds of formula (I): wherein A is a 5-membered heteroaryl ring are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38, such as rheumatoid arthritis.

  式(I)的化合物：其中A是一个5-成员杂环芳基环，是p38激酶的抑制剂，可用于治疗由p38激酶活性介导的疾病或疾病状态，或由p38活性产生的细胞因子介导的疾病状态，如类风湿性关节炎。